CN119684299A - 作为kcc2调节剂的稠合的嘧啶化合物 - Google Patents
作为kcc2调节剂的稠合的嘧啶化合物 Download PDFInfo
- Publication number
- CN119684299A CN119684299A CN202411881248.3A CN202411881248A CN119684299A CN 119684299 A CN119684299 A CN 119684299A CN 202411881248 A CN202411881248 A CN 202411881248A CN 119684299 A CN119684299 A CN 119684299A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- dihydro
- optionally substituted
- pyrimidin
- pyrrolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989104P | 2020-03-13 | 2020-03-13 | |
| US62/989,104 | 2020-03-13 | ||
| CN202180020856.3A CN115298182B (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| PCT/EP2021/056393 WO2021180952A1 (en) | 2020-03-13 | 2021-03-12 | Fused pyrimidine compounds as kcc2 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180020856.3A Division CN115298182B (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119684299A true CN119684299A (zh) | 2025-03-25 |
Family
ID=74874882
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411881248.3A Pending CN119684299A (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| CN202411881483.0A Pending CN119735594A (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| CN202180020856.3A Active CN115298182B (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| CN202411881526.5A Pending CN119684300A (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411881483.0A Pending CN119735594A (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| CN202180020856.3A Active CN115298182B (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
| CN202411881526.5A Pending CN119684300A (zh) | 2020-03-13 | 2021-03-12 | 作为kcc2调节剂的稠合的嘧啶化合物 |
Country Status (25)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
| CN117843618A (zh) * | 2022-08-29 | 2024-04-09 | 北京沐华生物科技有限责任公司 | 一种ep300/cbp调节剂及其制备方法和用途 |
| CN121241048A (zh) * | 2023-04-05 | 2025-12-30 | 艾索尼斯治疗公司 | Kcc2增强剂及其用途 |
| US20260191874A1 (en) * | 2024-03-06 | 2026-07-09 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of autism spectrum disorder, obsessive compulsive disorder and tics |
| WO2025188955A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of psychosis and psychotic disorders |
| WO2025188977A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of addiction and insomnia |
| WO2025188976A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neurodegenerative disorders |
| US20250281498A1 (en) * | 2024-03-06 | 2025-09-11 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies |
| WO2025188973A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of 22q11.2 deletion/duplication syndromes |
| WO2025188951A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of seizure disorders |
| WO2025188953A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain |
| WO2025188979A1 (en) * | 2024-03-06 | 2025-09-12 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds and pridopidine for treatment of huntington's disease |
| US20260108529A1 (en) * | 2024-10-23 | 2026-04-23 | Ovid Therapeutics Inc. | Fused amino pyrimidine compounds for treatment of tinnitus, acute sensorineural hearing loss, age-related hearing loss, and meniere's disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3398152B2 (ja) | 1993-10-12 | 2003-04-21 | ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー | １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体 |
| US20090099195A1 (en) * | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| AR079814A1 (es) * | 2009-12-31 | 2012-02-22 | Otsuka Pharma Co Ltd | Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| JP7399848B2 (ja) * | 2017-09-01 | 2023-12-18 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤 |
| KR20210050493A (ko) * | 2018-05-25 | 2021-05-07 | 더 칠드런스 메디칼 센터 코포레이션 | 척수 손상의 치료 방법 |
-
2021
- 2021-03-12 RS RS20231022A patent/RS64823B1/sr unknown
- 2021-03-12 KR KR1020227035465A patent/KR20220152319A/ko not_active Ceased
- 2021-03-12 SI SI202130073T patent/SI4103566T1/sl unknown
- 2021-03-12 FI FIEP21712145.8T patent/FI4103566T3/fi active
- 2021-03-12 JP JP2022554784A patent/JP7793529B2/ja active Active
- 2021-03-12 PT PT217121458T patent/PT4103566T/pt unknown
- 2021-03-12 EP EP21712145.8A patent/EP4103566B1/en active Active
- 2021-03-12 PE PE2022001943A patent/PE20230106A1/es unknown
- 2021-03-12 AU AU2021234134A patent/AU2021234134B2/en active Active
- 2021-03-12 PL PL21712145.8T patent/PL4103566T3/pl unknown
- 2021-03-12 CN CN202411881248.3A patent/CN119684299A/zh active Pending
- 2021-03-12 HU HUE21712145A patent/HUE064037T2/hu unknown
- 2021-03-12 CN CN202411881483.0A patent/CN119735594A/zh active Pending
- 2021-03-12 BR BR112022018173A patent/BR112022018173A2/pt unknown
- 2021-03-12 ES ES21712145T patent/ES2962136T3/es active Active
- 2021-03-12 MX MX2022011354A patent/MX2022011354A/es unknown
- 2021-03-12 IL IL296265A patent/IL296265B2/en unknown
- 2021-03-12 WO PCT/EP2021/056393 patent/WO2021180952A1/en not_active Ceased
- 2021-03-12 US US17/911,051 patent/US12617795B2/en active Active
- 2021-03-12 CA CA3171192A patent/CA3171192A1/en active Pending
- 2021-03-12 CN CN202180020856.3A patent/CN115298182B/zh active Active
- 2021-03-12 LT LTEPPCT/EP2021/056393T patent/LT4103566T/lt unknown
- 2021-03-12 SM SM20230384T patent/SMT202300384T1/it unknown
- 2021-03-12 DK DK21712145.8T patent/DK4103566T3/da active
- 2021-03-12 CN CN202411881526.5A patent/CN119684300A/zh active Pending
- 2021-03-12 HR HRP20231314TT patent/HRP20231314T1/hr unknown
-
2022
- 2022-09-01 CL CL2022002386A patent/CL2022002386A1/es unknown
- 2022-09-09 CO CONC2022/0012884A patent/CO2022012884A2/es unknown
-
2025
- 2025-09-12 JP JP2025151939A patent/JP2025186368A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115298182B (zh) | 作为kcc2调节剂的稠合的嘧啶化合物 | |
| JP7153647B2 (ja) | Ｊａｋファミリーのキナーゼの阻害剤としてのイミダゾピロロピリジン | |
| CN108467369B (zh) | 作为激酶抑制剂的联芳基酰胺化合物 | |
| JP5524084B2 (ja) | Ｈｓｐ９０阻害剤としてのオキシム誘導体 | |
| WO2021239133A1 (zh) | 作为axl抑制剂的嘧啶类化合物 | |
| US20220127281A1 (en) | Heteroaryl compounds that inhibit g12c mutant ras proteins | |
| CN109863151B (zh) | 用于治疗正粘病毒感染的稠合三环哒嗪酮化合物 | |
| EP3761980A1 (en) | Amino acid compounds and methods of use | |
| EP3686197B1 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
| WO2024259171A9 (en) | Keap1 inhibitors and uses thereof | |
| JP7851393B2 (ja) | 癌の治療のためのｈｐｋ１阻害剤としての置換ピラジン－２－カルボキサミド阻害剤 | |
| US8273890B2 (en) | Thiophene-imidazopyridines | |
| CN115279757A (zh) | 用于治疗和预防hiv感染的抗病毒药剂的嘧啶系双环化合物 | |
| CN110225912B (zh) | Gsk-3抑制剂 | |
| HK40085963A (en) | Fused pyrimidine compounds as kcc2 modulators | |
| HK40085963B (en) | Fused pyrimidine compounds as kcc2 modulators | |
| CN117015528A (zh) | 作为激酶抑制剂的吲哚衍生物 | |
| WO2026015873A1 (en) | Stat6 inhibitors and uses thereof | |
| WO2025015167A2 (en) | Erastin ketone analogs and uses thereof | |
| EP4592286A1 (en) | Macrocyclic nitrogen-containing crown ether compound and use thereof as protein kinase inhibitor | |
| KR20220123446A (ko) | Btk 억제제 | |
| HK40044282A (en) | Amino acid compounds and methods of use | |
| HK40009791A (en) | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |